Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report

A man in his late 40s was diagnosed with clinical stage 4B lung adenocarcinoma with a PD-L1 tumor proportion score of 100% and high tumor mutational burden. A partial response was achieved after administration of pembrolizumab. The patient received two doses of a SARS-CoV-2 vaccine (BNT162b2) after...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Koki, Fukuda, Kensuke, Kawakami, Masanori, Mitani, Akihisa, Tanaka, Goh, Kage, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601772/
https://www.ncbi.nlm.nih.gov/pubmed/37900823
http://dx.doi.org/10.1159/000533705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601772/
https://www.ncbi.nlm.nih.gov/pubmed/37900823
http://dx.doi.org/10.1159/000533705

Ejemplares similares